Annovis Bio, Inc.
ANVSStock
$1.74−40.21%52W
Market Cap$74.02M
P/E—
Div yield—
Beta1.22
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-64.26%
Price vs S&P 500 (4W)-3.54%
VGM Score33.53
Market Capitalization$74.02M
Earnings Surprise History
Q1 26-0.63est. -0.40
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.10
4.10
4.13
4.13
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ANVSAnnovis Bio, Inc. | — | — | D | $1.74 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Annovis Bio is a clinical-stage biopharmaceutical company developing therapies for neurodegenerative diseases, primarily Alzheimer's and Parkinson's disease. Its pipeline includes Buntanetap for chronic neurodegeneration, ANVS405 for acute neurodegeneration, and ANVS301 for Alzheimer's disease.